Nkarta to Participate in March Investor Conferences
Rhea-AI Summary
Nkarta (Nasdaq: NKTX), a biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies, has announced its upcoming participation in two major investor conferences in March 2025.
The company will be featured in fireside chat sessions at the:
- TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 3:10 p.m. ET
- Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, at 3:00 p.m. ET
Investors and interested parties can access simultaneous webcasts of both events through Nkarta's website at www.nkartatx.com. Recordings will remain available on the company's Investors section for approximately 90 days after the events.
Positive
- Nkarta's participation in two major healthcare investor conferences indicates strong institutional interest in their NK cell therapy platform
- The company is maintaining visibility with investors through high-profile conference appearances
- Providing public webcasts of the presentations demonstrates transparency and accessibility for all investors
Negative
- The press release contains information about Nkarta's actual product pipeline or development progress
- No specific updates on clinical trials or regulatory milestones were mentioned
- The announcement doesn't include any financial information or business developments
News Market Reaction
On the day this news was published, NKTX declined 4.57%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences:
TD Cowen 45th Annual Health Care Conference
March 3, 2025
3:10 p.m. ET – fireside chat
Leerink Partners 2025 Global Healthcare Conference
March 10, 2025
3:00 p.m. ET – fireside chat
A simultaneous webcast of the events will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
FAQ
When is Nkarta (NKTX) presenting at the TD Cowen Healthcare Conference in 2025?
What time is Nkarta's (NKTX) presentation at the Leerink Partners 2025 Global Healthcare Conference?
How can investors access Nkarta's (NKTX) March 2025 conference presentations?
What type of cell therapies is Nkarta (NKTX) developing according to their March 2025 investor conference announcement?
How many investor conferences will Nkarta (NKTX) participate in during March 2025?
